Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond

You may also be interested in...



Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says

TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa

Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says

TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa

South Korea’s BiocurePharm To Produce Biosimilars In Thailand

SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13

Related Content

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel